Stock A032300 KOREA PHARMA CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

KOREA PHARMA Co., Ltd. Stock

Equities

A032300

KR7032300006

Pharmaceuticals

End-of-day quote Korea S.E.
Other stock markets
 06:00:00 2024-05-30 pm EDT 		5-day change 1st Jan Change
17,760 KRW +0.06% Intraday chart for KOREA PHARMA Co., Ltd. -5.98% -24.90%
May. 28 NetScientific backs Wanda; Inspirit Energy wins deal AN
May. 28 Korea Pharma Co., Ltd Submits A New Drug Application to the Korean Ministry of Food and Drug Safety for the Review and Approval of Accrufer to Treat Patients with Iron Deficiency Anaemia in Korea CI

Financials

Sales 2022 81.03B 58.67M Sales 2023 83.24B 60.27M Capitalization 258B 187M
Net income 2022 -1.12B -810K Net income 2023 83M 60.09K EV / Sales 2022 2.78 x
Net cash position 2022 8.45B 6.12M Net cash position 2023 13.45B 9.74M EV / Sales 2023 2.94 x
P/E ratio 2022
-209 x
P/E ratio 2023
3,079 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 35.4%
More Fundamentals * Assessed data

Chart KOREA PHARMA Co., Ltd.

Dynamic Chart

Latest news about KOREA PHARMA Co., Ltd.

NetScientific backs Wanda; Inspirit Energy wins deal AN
Korea Pharma Co., Ltd Submits A New Drug Application to the Korean Ministry of Food and Drug Safety for the Review and Approval of Accrufer to Treat Patients with Iron Deficiency Anaemia in Korea CI
Astrogen Co.,Ltd. announced that it has received KRW 2.999998662 billion in funding from KOREA PHARMA Co., Ltd. CI
KOREA PHARMA Co., Ltd. announced that it has received KRW 23 billion in funding from Samsung Securities Co., Ltd., KB Securities Co., Ltd., NH Investment & Securities Co., Ltd., Mirae Asset Securities Co., Ltd., EBEST Investment & Securities Co., Ltd. CI
KOREA PHARMA Co., Ltd. announced that it expects to receive KRW 23 billion in funding from Samsung Securities Co., Ltd., KB Securities Co., Ltd., NH Investment & Securities Co., Ltd., Mirae Asset Securities Co., Ltd., EBEST Investment & Securities Co., Ltd. and others CI
Astrogen Co.,Ltd. announced that it expects to receive KRW 2.999998662 billion in funding from KOREA PHARMA Co., Ltd. CI
KOREA PHARMA Co., Ltd.(KOSDAQ:A032300) dropped from S&P Global BMI Index CI
KOREA PHARMA Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
KOREA PHARMA Co., Ltd. announced that it has received KRW 50 billion in funding CI
KOREA PHARMA Co., Ltd. announced that it expects to receive KRW 50 billion in funding CI
KOREA PHARMA Co., Ltd.(KOSDAQ:A032300) added to S&P Global BMI Index CI
KOREA PHARMA Co., Ltd. has completed an IPO in the amount of KRW 29.187 billion. CI
KOREA PHARMA Co., Ltd. has filed an IPO. CI
More news

Press releases KOREA PHARMA Co., Ltd.

Shield Therapeutics plc - Full Year Trading Update AQ
Shield announces regulatory pathway and timelines for Accrufer approval in the Republic of Korea AQ
Shield Therapeutics : Licence agreement secured in Republic of Korea for Accrufer AQ
More press releases

Quotes and Performance

1 day+0.06%
1 week-5.98%
1 month-7.74%
3 months-15.02%
6 months-9.20%
Current year-24.90%
More quotes

Highs and lows

1 week
17 700.00
Extreme 17700
19 060.00
1 month
17 700.00
Extreme 17700
19 580.00
Current year
17 700.00
Extreme 17700
25 400.00
1 year
15 020.00
Extreme 15020
29 450.00
3 years
15 020.00
Extreme 15020
85 500.00
5 years
13 100.00
Extreme 13100
94 800.00
10 years
13 100.00
Extreme 13100
94 800.00
More quotes

Managers and Directors - KOREA PHARMA Co., Ltd.

Managers TitleAgeSince
Eun-Hee Park CEO
 Chief Executive Officer 57 -
Yong-Ki Park DFI
 Director of Finance/CFO 63 -
Seung-Hee Han CTO
 Chief Tech/Sci/R&D Officer 57 -
Members of the board TitleAgeSince
Jin-Hyoung Kim BRD
 Director/Board Member 47 22-03-29
Jae-Don Park BRD
 Director/Board Member 88 -
Eun-Hee Park CEO
 Chief Executive Officer 57 -
More insiders

Quotes

Date Price Change Volume
24-05-31 17,760 +0.06% 20,856
24-05-30 17,750 -3.06% 47,585
24-05-29 18,310 -1.19% 18,245
24-05-28 18,530 -0.38% 28,755
24-05-27 18,600 -1.54% 21,424

End-of-day quote Korea S.E., May 30, 2024

More quotes

Company Profile

Korea Pharma Co Ltd is a Korea-based company mainly engaged in the manufacture and sale of medicinal products. The Company's main products include digestive system solvents, antidepressants, blood circulation agents, antidementia drugs, schizophrenia medicines and others.
Sector
Pharmaceuticals
Calendar
2024-08-08 - Q2 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Chiffre d''affaires - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
KOREA PHARMA CO., LTD. Stock KOREA PHARMA Co., Ltd.
-24.90% 141M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+40.73% 734B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+32.83% 591B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.30% 350B
MERCK & CO., INC. Stock Merck & Co., Inc.
+15.15% 315B
ABBVIE INC. Stock AbbVie Inc.
+4.05% 276B
ASTRAZENECA PLC Stock AstraZeneca PLC
+15.00% 238B
NOVARTIS AG Stock Novartis AG
+9.78% 206B
ROCHE HOLDING AG Stock Roche Holding AG
-5.52% 204B
AMGEN INC. Stock Amgen Inc.
+6.17% 161B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. A032300 Stock